Odyssey Health's sublicense deal for BreastCheck cancelled by NeuRX due to breach of Davion contract

Odyssey Health, Inc.

NeuRX revoked its Oct 2025 agreement with Odyssey to sublicense Davion's BreastCheck product, effective immediately.
NeuRX admits it lacked legal right to sublicense without Davion's written consent; Davion would have declined approval.
Cancellation follows notice that NeuRX breached representations and warranties in the definitive agreement.
Davion demands Odyssey withdraw public statements that it holds a BreastCheck sublicense.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.